Search

Your search keyword '"I S, Protasov"' showing total 2 results
Start Over Author "I S, Protasov"
2 results on '"I S, Protasov"'

1. Some Questions of the Mixed Anxiety-Depressive Disorders in Patients with Cerebellar Stroke in the Early Period of Convalescence

Author

V. A. Kutashov, O. V. Ulyanova, I. S. Protasov, A. P. Skorokhodov, O. V. Zolotaryov, L. S. Nemykh, E. S. Ananyeva, A. A. Dudina, and M. V. Uvarova

Subjects
acute cerebrovascular accident, cerebellar stroke, mixed anxiety–depressive disorders, Medicine
Abstract

Background: The objective of this study was to investigate the medico-social and mixed anxiety–depressive disorders (MADD) in patients with cerebellar stroke (CS) in the early recovery period. Methods and Results: The study included 140 patients (87/62% men and 53/38% women) with average age of 57.2±2.2 years. Patients were examined in the early recovery period (6 months from the onset of the disease). The level of anxiety and depression was assessed using the Hamilton Rating Scale for Depression. In the early recovery period from CS, the difeferent types of MADD were diagnosed. A high level of depression was found in 3.57% of patients, the average level - in 27.86%, mild depression - in 33.57% of patients, and the absence of depressive symptoms in 35% of patients. A high level of anxiety in 17.50% of CS patients, a moderate level of anxiety in 47.86%, a low anxiety level in 45.0%, and no anxiety in 2(1.43%) patients. Conclusion: Different levels of MADD in CS patients in the early period of convalescence need individual specific treatment.

Published
2020
Full Text
View/download PDF

2. [Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation]

Author

K Z, Bakhtiiarova, O V, Bragina, Ia V, Vlasov, I V, Greshnova, E P, Evdoshenko, E I, Ivanishenkova, E I, Kairbekova, E N, Karnaukhova, N A, Korotkevich, A V, Leliukhina, I S, Protasov, E V, Rybina, A I, Sazhnev, A A, Skoromets, O A, Soldatova, Iu V, Trinitatskiĭ, A S, Fedianin, S N, Chelnokova, V D, Shabanova, R R, Sharipova, E A, Shchegol'kova, and I A, Iampol'skaia-Gosteva

Subjects
Adult, Male, Adolescent, Middle Aged, Russia, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Treatment Outcome, Humans, Female, Prospective Studies, Biosimilar Pharmaceuticals, Interferon beta-1a, Retrospective Studies
Abstract

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system. Nowadays some disease-modifying drugs (DMD) in the Russian Federation (RF) are biosimilars. Their full spectrum of tolerability and efficacy is to be determined. Here we present results of two retrospective-prospective studies on efficacy and safety of a biosimilar interferon beta-1a (genfaxon) in treatment of MS in the RF.determination of safety and efficacy profile of genfaxon in a routine neurological practice in the RF.Trials were performed in 18 MS centers in the RF. A total of 649 patients aged from 18 to 68 years with the EDSS score no more than 6.0 were treated with genfaxon for 12 months. The first group was comprised of 'naïve' patients without previous history of DMD administration. There were patients in the second group which have already received some of DMD. Statistical analysis was performed with the help of significance criteria (χ-square), t-criteria of Student for analysis of independent samplings.There were no serious adverse events during the period of the study. "Naïve" patients had significantly lower number of adverse events, than patients with previous history of DMD usage. Efficacy results were comparable with results published for the Rebif.Data, received from the studies show equal efficacy and tolerability of genfaxon compared with original DMD Rebif.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results